CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) based on the first 29 amino acids of native GRF (sermorelin). Two forms are commonly encountered in research: CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) and CJC-1295 with DAC (Drug Affinity Complex).
Without DAC (Mod GRF 1-29)
This version incorporates four amino acid substitutions (positions 2, 8, 15, and 27) that protect the peptide from enzymatic cleavage by DPP-IV. The result is a half-life of approximately 30 minutes compared to native GRF’s ~7 minutes, while preserving the pulsatile GH release pattern.
With DAC
The DAC (Drug Affinity Complex) version adds a lysine-linked maleimidopropionamide moiety that covalently binds to serum albumin after injection. This extends the half-life to approximately 6โ8 days, producing a continuous elevation of GH levels rather than pulsatile release.
Research Considerations
The choice between DAC and no-DAC variants affects experimental design. The pulsatile pattern of CJC-1295 without DAC more closely mimics physiological GH secretion, while the DAC version provides sustained receptor activation useful for studying chronic GH elevation effects.